Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent covering the company's lead drug candidate MYDICAR, a genetically targeted enzyme replacement therapy for advanced heart failure. The patent will be issued to The Regents of the University of California and licensed exclusively to Celladon.
When issued, the patent will cover the use of all adeno-associated viral vectors (AAV) and routes of administration, including intracoronary, for delivery of the SERCA2a gene for the treatment of heart failure. The patent will have a term extending to at least 2023, depending on further possible time extensions due to any regulatory delays. This patent is part of Celladon's broad intellectual property portfolio for MYDICAR and related technologies for the treatment of heart failure. Corresponding patent applications are currently pending in Europe, China, Japan and other countries.
"The new patent solidifies Celladon's intellectual property position in the U.S. for MYDICAR," said Krisztina M. Zsebo, Ph.D., the company's president and chief executive officer. "Our lead drug candidate represents an innovative approach to treating advanced heart failure. Specifically, MYDICAR@ treatment involves a one-time outpatient infusion in a cardiac catheterization laboratory, similar to what patients experience when undergoing an angiogram.
MYDICAR is designed to restore levels of the SERCA2a enzyme, which is known to play a key role in the progression of heart failure. In the current Phase 2 portion of the Phase 1/2 clinical trial, we intend to demonstrate the safety of MYDICAR and provide evidence that the drug candidate has the potential to halt or reverse the progression of heart failure in patients."